CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma’s proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases... Show more
Carisma Therapeutics, Inc. (CARM) is a biotechnology company focused on developing engineered macrophage immunotherapies for cancer and liver fibrosis. Its pipeline includes preclinical and early-stage clinical candidates like CT-2401 for liver fibrosis and CT-1119, a mesothelin-targeted CAR-Monocyte therapy in Phase I for solid tumors such as pancreatic, ovarian, and lung cancers. Previously listed on Nasdaq, CARM has shifted to OTC trading following delisting.
The company's business model relies on innovative cell therapy platforms, including collaborations like one with Moderna for oncology gene therapies. In the competitive biotech landscape, CARM targets niche immunotherapy areas but faces challenges from high cash burn, clinical risks, and funding constraints typical of clinical-stage biotechs. These fundamentals, combined with recent corporate restructuring, explain the stock's persistent weakness as investors demand progress on pipeline milestones amid limited liquidity.
Over the last 30 days, CARM stock price dropped from approximately $0.042 to $0.033, marking a -21% decline. The movement was volatile yet downward-trending, with low daily volumes around 30,000-90,000 shares, reflecting range-bound trading between $0.032 and $0.044 amid thin liquidity on OTC markets.
For the past quarter, the stock fell about -23% from around $0.043 to the current $0.033 level. Performance has been steadily negative, punctuated by sharp drops tied to corporate announcements, with overall range-bound behavior in the sub-$0.05 range due to delisting impacts and sector headwinds.
The 30-day downturn in CARM stock stems primarily from lingering effects of its Nasdaq delisting and shift to OTCID trading, which began October 13, 2025, reducing visibility and institutional access. Low trading volumes exacerbated price swings, with shares trading thinly between $0.03 and $0.04.
Absence of new clinical data, earnings, or partnerships fueled bearish sentiment. Broader biotech sector weakness, including investor caution toward small-cap clinical-stage firms amid high interest rates, pressured the stock. No major analyst updates occurred, but OTC status inherently limits upside potential and increases volatility.
The quarterly decline was dominated by the October 2025 Nasdaq suspension due to noncompliance with bid price, market value, and public float rules, causing an immediate 40%+ plunge as trading moved to less liquid OTC markets. December 2025 announcements of voluntary delisting and SEC deregistration plans further eroded confidence, signaling wind-down and reduced reporting obligations.
Macro factors like elevated rates squeezed biotech funding, while competitive dynamics in cell therapy favored larger players. Institutional selling and lack of pipeline catalysts compounded the drop, with the stock stabilizing at micro-cap levels but showing no rebound amid ongoing operational challenges.
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots from among hundreds that analyze and trade thousands of tickers across various markets. These curated bots represent the most relevant and high-achieving strategies based on recent performance metrics, adapting to current market conditions. Strategies differ widely, including trend-following, mean reversion, scalping, or momentum plays, with varying timeframes from intraday to long-term holds. Performance is tracked via win rates, profit factors, and drawdowns, helping users identify bots suited to their risk tolerance and goals. Explore Trending AI Robots today to integrate cutting-edge automation into your trading.
Investors should monitor any updates on strategic alternatives outlined in March 2025 corporate revisions, including potential asset sales or partnerships. Progress on remaining pipeline programs, such as CT-1119 clinical data or CT-2401 preclinical advances, could influence sentiment.
Biotech sector trends, including M&A activity and funding environment, remain key. Macro shifts like interest rate changes or regulatory developments in cell therapies warrant attention. Risks include further liquidity erosion post-deregistration and operational wind-down execution, alongside catalysts like new collaborations.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.